Dan Mitchell
Founder at Sequel Venture Partners LLC
Net worth: 2 261 $ as of 2024-05-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| C. Dekker | M | 60 | 18 years | |
| Dale Schmaltz | M | - |
Bolder Surgical LLC
 Bolder Surgical LLC Medical SpecialtiesHealth Technology Bolder Surgical LLC engages in the design, development, and manufacture of surgical devices. Its products include JustRight Vessel Sealing System, JustRight 5mm Stapler, and EcoSac 5mm Tissue Retrieval System. The company was founded by Russell Lindemann, Scott Drake, Dale Schmaltz, Jenifer Kennedy, Patricia Moroney Hoag, David R. Duncan, and Steve Rothenberg on January 22, 2010 and is headquartered in Louisville, CO. | 14 years |
| Robert Kline | M | - |
Bolder Surgical LLC
Bolder Surgical LLC Medical SpecialtiesHealth Technology Bolder Surgical LLC engages in the design, development, and manufacture of surgical devices. Its products include JustRight Vessel Sealing System, JustRight 5mm Stapler, and EcoSac 5mm Tissue Retrieval System. The company was founded by Russell Lindemann, Scott Drake, Dale Schmaltz, Jenifer Kennedy, Patricia Moroney Hoag, David R. Duncan, and Steve Rothenberg on January 22, 2010 and is headquartered in Louisville, CO. | 7 years |
| Augustine Lawlor | M | 67 |
Replidyne, Inc.
 Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 22 years |
| John T. Greff | M | - |
Sequel Venture Partners LLC
 Sequel Venture Partners LLC Investment ManagersFinance Sequel Venture Partners LLC (Sequel Venture Partners) is a venture capital firm founded in 1996 by Kinney Johnson, Daniel Mitchell and Thomas Washing. The firm is headquartered in Boulder, Colorado. | 28 years |
| Kinney L. Johnson | M | - |
Capital Health Venture Partners
 Capital Health Venture Partners Investment ManagersFinance Capital Health Venture Partners is an alternative investment manager. The private company is based in Chicago, IL and has subsidiaries in the United States. The company was founded in 1985 by Daniel J. Mitchell.
Sequel Venture Partners LLC
Sequel Venture Partners LLC Investment ManagersFinance Sequel Venture Partners LLC (Sequel Venture Partners) is a venture capital firm founded in 1996 by Kinney Johnson, Daniel Mitchell and Thomas Washing. The firm is headquartered in Boulder, Colorado. | 39 years |
| Craig F. Plato | M | - |
Plato BioPharma, Inc.
 Plato BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Inotiv, Inc., Plato BioPharma, Inc. develops preclinical drug discovery. The company is based in Westminster, CO. Plato BioPharma was acquired by Inotiv, Inc. on October 04, 2021 for $14.76 million. The company was founded in 2010 by Craig F. Plato. Craig F. Plato has been the CEO since 2010. | 14 years |
| Jenifer Kennedy | M | - |
Bolder Surgical LLC
Bolder Surgical LLC Medical SpecialtiesHealth Technology Bolder Surgical LLC engages in the design, development, and manufacture of surgical devices. Its products include JustRight Vessel Sealing System, JustRight 5mm Stapler, and EcoSac 5mm Tissue Retrieval System. The company was founded by Russell Lindemann, Scott Drake, Dale Schmaltz, Jenifer Kennedy, Patricia Moroney Hoag, David R. Duncan, and Steve Rothenberg on January 22, 2010 and is headquartered in Louisville, CO. | 14 years |
| Patricia Moroney Hoag | F | - |
Bolder Surgical LLC
Bolder Surgical LLC Medical SpecialtiesHealth Technology Bolder Surgical LLC engages in the design, development, and manufacture of surgical devices. Its products include JustRight Vessel Sealing System, JustRight 5mm Stapler, and EcoSac 5mm Tissue Retrieval System. The company was founded by Russell Lindemann, Scott Drake, Dale Schmaltz, Jenifer Kennedy, Patricia Moroney Hoag, David R. Duncan, and Steve Rothenberg on January 22, 2010 and is headquartered in Louisville, CO. | 14 years |
| Jacob Ma-Weaver | M | 37 | 2 years | |
| James Flynn | M | 43 | 2 years | |
| Tom G. Washing | M | - |
Sequel Venture Partners LLC
Sequel Venture Partners LLC Investment ManagersFinance Sequel Venture Partners LLC (Sequel Venture Partners) is a venture capital firm founded in 1996 by Kinney Johnson, Daniel Mitchell and Thomas Washing. The firm is headquartered in Boulder, Colorado. | 28 years |
| Robert M. di Scipio | M | - |
Skyland Analytics, Inc.
 Skyland Analytics, Inc. Packaged SoftwareTechnology Services Skyland Analytics, Inc. provides power of manufacturing informatics software, IT systems and data analytics services. Its services include informatics, risk management and discoverant. The company was founded by Robert M. Di Scipio and is headquartered in Niwot, CO. | - |
| Anders Hove | M | 58 | 7 years | |
| Greg Krueger | M | - |
ViroCyt, Inc.
 ViroCyt, Inc. Miscellaneous Commercial ServicesCommercial Services ViroCyt, Inc. develops life science instrumentation and assays products for the analysis of viruses and microorganisms. The company was founded in 2012 and is headquartered in Broomfield, CO. | 9 years |
| Albert Petkus | M | - |
Plato BioPharma, Inc.
Plato BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Inotiv, Inc., Plato BioPharma, Inc. develops preclinical drug discovery. The company is based in Westminster, CO. Plato BioPharma was acquired by Inotiv, Inc. on October 04, 2021 for $14.76 million. The company was founded in 2010 by Craig F. Plato. Craig F. Plato has been the CEO since 2010. | - |
| Claire Bronstein | F | - |
Bolder Surgical LLC
Bolder Surgical LLC Medical SpecialtiesHealth Technology Bolder Surgical LLC engages in the design, development, and manufacture of surgical devices. Its products include JustRight Vessel Sealing System, JustRight 5mm Stapler, and EcoSac 5mm Tissue Retrieval System. The company was founded by Russell Lindemann, Scott Drake, Dale Schmaltz, Jenifer Kennedy, Patricia Moroney Hoag, David R. Duncan, and Steve Rothenberg on January 22, 2010 and is headquartered in Louisville, CO. | - |
| Kristin Joly | F | - |
Plato BioPharma, Inc.
Plato BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Inotiv, Inc., Plato BioPharma, Inc. develops preclinical drug discovery. The company is based in Westminster, CO. Plato BioPharma was acquired by Inotiv, Inc. on October 04, 2021 for $14.76 million. The company was founded in 2010 by Craig F. Plato. Craig F. Plato has been the CEO since 2010. | - |
| Walter R. Young | M | 78 |
ViroCyt, Inc.
ViroCyt, Inc. Miscellaneous Commercial ServicesCommercial Services ViroCyt, Inc. develops life science instrumentation and assays products for the analysis of viruses and microorganisms. The company was founded in 2012 and is headquartered in Broomfield, CO. | - |
| Michael Olszowy | M | - |
ViroCyt, Inc.
ViroCyt, Inc. Miscellaneous Commercial ServicesCommercial Services ViroCyt, Inc. develops life science instrumentation and assays products for the analysis of viruses and microorganisms. The company was founded in 2012 and is headquartered in Broomfield, CO. | - |
| Kathy L. Rowlen | M | - |
ViroCyt, Inc.
ViroCyt, Inc. Miscellaneous Commercial ServicesCommercial Services ViroCyt, Inc. develops life science instrumentation and assays products for the analysis of viruses and microorganisms. The company was founded in 2012 and is headquartered in Broomfield, CO. | - |
| David Duncan | M | 58 |
Bolder Surgical LLC
Bolder Surgical LLC Medical SpecialtiesHealth Technology Bolder Surgical LLC engages in the design, development, and manufacture of surgical devices. Its products include JustRight Vessel Sealing System, JustRight 5mm Stapler, and EcoSac 5mm Tissue Retrieval System. The company was founded by Russell Lindemann, Scott Drake, Dale Schmaltz, Jenifer Kennedy, Patricia Moroney Hoag, David R. Duncan, and Steve Rothenberg on January 22, 2010 and is headquartered in Louisville, CO. | 14 years |
| David Withers | M | 52 |
Skyland Analytics, Inc.
Skyland Analytics, Inc. Packaged SoftwareTechnology Services Skyland Analytics, Inc. provides power of manufacturing informatics software, IT systems and data analytics services. Its services include informatics, risk management and discoverant. The company was founded by Robert M. Di Scipio and is headquartered in Niwot, CO. | - |
| Mark T. Lupa | M | - |
ViroCyt, Inc.
ViroCyt, Inc. Miscellaneous Commercial ServicesCommercial Services ViroCyt, Inc. develops life science instrumentation and assays products for the analysis of viruses and microorganisms. The company was founded in 2012 and is headquartered in Broomfield, CO. | - |
| Larry Gold | M | 82 |
Plato BioPharma, Inc.
Plato BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Inotiv, Inc., Plato BioPharma, Inc. develops preclinical drug discovery. The company is based in Westminster, CO. Plato BioPharma was acquired by Inotiv, Inc. on October 04, 2021 for $14.76 million. The company was founded in 2010 by Craig F. Plato. Craig F. Plato has been the CEO since 2010. | - |
| J. Carter McNabb | M | 52 |
Bolder Surgical LLC
Bolder Surgical LLC Medical SpecialtiesHealth Technology Bolder Surgical LLC engages in the design, development, and manufacture of surgical devices. Its products include JustRight Vessel Sealing System, JustRight 5mm Stapler, and EcoSac 5mm Tissue Retrieval System. The company was founded by Russell Lindemann, Scott Drake, Dale Schmaltz, Jenifer Kennedy, Patricia Moroney Hoag, David R. Duncan, and Steve Rothenberg on January 22, 2010 and is headquartered in Louisville, CO. | 5 years |
| Timothy Connor | M | - |
Sequel Venture Partners LLC
Sequel Venture Partners LLC Investment ManagersFinance Sequel Venture Partners LLC (Sequel Venture Partners) is a venture capital firm founded in 1996 by Kinney Johnson, Daniel Mitchell and Thomas Washing. The firm is headquartered in Boulder, Colorado. | 24 years |
| Richard Packer | M | 66 |
Bolder Surgical LLC
Bolder Surgical LLC Medical SpecialtiesHealth Technology Bolder Surgical LLC engages in the design, development, and manufacture of surgical devices. Its products include JustRight Vessel Sealing System, JustRight 5mm Stapler, and EcoSac 5mm Tissue Retrieval System. The company was founded by Russell Lindemann, Scott Drake, Dale Schmaltz, Jenifer Kennedy, Patricia Moroney Hoag, David R. Duncan, and Steve Rothenberg on January 22, 2010 and is headquartered in Louisville, CO. | 5 years |
| Jack Ball | M | 77 |
ViroCyt, Inc.
ViroCyt, Inc. Miscellaneous Commercial ServicesCommercial Services ViroCyt, Inc. develops life science instrumentation and assays products for the analysis of viruses and microorganisms. The company was founded in 2012 and is headquartered in Broomfield, CO. | 11 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Nebojsa Janjic | M | 63 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 8 years |
| Chris Christoffersen | M | 86 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | - |
| J. William Freytag | M | 72 | 8 years | |
| Christopher Ozeroff | M | 65 | 31 years | |
| David Vitale | M | 78 |
First National Bank of Chicago (Illinois)
| 12 years |
| Ulrike Steinhorst | F | 72 | - | |
| Jason A. Leverone | M | 50 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 3 years |
| Brian L. Selby | M | 62 | 14 years | |
| Mark L. Smith | M | 72 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 3 years |
| Rick Patch | M | - |
Sequel Venture Partners LLC
Sequel Venture Partners LLC Investment ManagersFinance Sequel Venture Partners LLC (Sequel Venture Partners) is a venture capital firm founded in 1996 by Kinney Johnson, Daniel Mitchell and Thomas Washing. The firm is headquartered in Boulder, Colorado. | 8 years |
| Paul Anthony Mieyal | M | 55 | - | |
| Pennina Safer | M | 67 | 3 years | |
| Raymond Woosley | M | 81 | 11 years | |
| Patrick M. Wheeler | M | 54 | 8 years | |
| S. Torres | M | 61 | 6 years | |
| Christopher Scoggins | M | - |
Sequel Venture Partners LLC
Sequel Venture Partners LLC Investment ManagersFinance Sequel Venture Partners LLC (Sequel Venture Partners) is a venture capital firm founded in 1996 by Kinney Johnson, Daniel Mitchell and Thomas Washing. The firm is headquartered in Boulder, Colorado. | 8 years |
| John H. Frenz | M | 68 | 7 years | |
| Nancy Casey | F | - |
Sequel Venture Partners LLC
Sequel Venture Partners LLC Investment ManagersFinance Sequel Venture Partners LLC (Sequel Venture Partners) is a venture capital firm founded in 1996 by Kinney Johnson, Daniel Mitchell and Thomas Washing. The firm is headquartered in Boulder, Colorado. | 10 years |
| Kirk Calhoun | M | 80 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 3 years |
| Sabrina B. Oei | F | - |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | - |
| Kirk A. Christoffersen | M | 56 | 11 years | |
| Karen Case | F | 65 |
First National Bank of Chicago (Illinois)
| 5 years |
| J. C. Lee | M | - |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | - |
| Daryl Overholt | M | - |
Sequel Venture Partners LLC
Sequel Venture Partners LLC Investment ManagersFinance Sequel Venture Partners LLC (Sequel Venture Partners) is a venture capital firm founded in 1996 by Kinney Johnson, Daniel Mitchell and Thomas Washing. The firm is headquartered in Boulder, Colorado. | 5 years |
| Thomas Montag | M | 67 |
First National Bank of Chicago (Illinois)
| 3 years |
| Dennis B. Tracey | M | - |
First National Bank of Chicago (Illinois)
| 6 years |
| Ian A. Critchley | M | - |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 6 years |
| Debra Marshall | M | - | 6 years | |
| Ingrid Bonde | F | 65 |
First National Bank of Chicago (Illinois)
| 2 years |
| Malcolm S. Sina | M | - |
First National Bank of Chicago (Illinois)
| 4 years |
| Ibrahim M. Ibrahim | M | 76 |
First National Bank of Chicago (Illinois)
| 2 years |
| Edward Brown | M | 61 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 2 years |
| Robert D. Sloan | M | 76 |
First National Bank of Chicago (Illinois)
| 7 years |
| Peter W. Letendre | M | 66 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 3 years |
| Donald J. Morrissey | M | 58 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 7 years |
| Geoff Duyk | M | 64 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 5 years |
| Adam Metz | M | 62 |
First National Bank of Chicago (Illinois)
| 4 years |
| Robert Schweitzer | M | 78 |
First National Bank of Chicago (Illinois)
| 6 years |
| Ron Bernal | M | 68 |
Sequel Venture Partners LLC
Sequel Venture Partners LLC Investment ManagersFinance Sequel Venture Partners LLC (Sequel Venture Partners) is a venture capital firm founded in 1996 by Kinney Johnson, Daniel Mitchell and Thomas Washing. The firm is headquartered in Boulder, Colorado. | 4 years |
| Jeffrey Rona | M | 55 | - | |
| Eric Christian Larson | M | - |
First National Bank of Chicago (Illinois)
| - |
| David Apelian | M | 59 | 8 years | |
| Kenneth J. Collins | M | 77 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 7 years |
| Roger M. Echols | M | 75 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 3 years |
| Peter W. Letebdre | M | - |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | - |
| Jill Clark | F | - |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 7 years |
| Barbara E. Baring | F | - |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 2 years |
| Matthew N. Johnson | M | 59 |
First National Bank of Chicago (Illinois)
| 7 years |
| Christopher D. Earl | M | 68 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 4 years |
| Christopher Graybill | M | - | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 79 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Dan Mitchell
- Personal Network
